Study on Zoledronic Acid for Patients with Hip Fractures: Evaluating Early Treatment Safety and Effectiveness

3 1 1

What is this study about?

This clinical trial is focused on studying the effects of the medication Zoledronic Acid in patients who have experienced a hip fracture. The trial is known as the ZEBRA trial. Zoledronic Acid is a type of medication called a bisphosphonate, which is used to help strengthen bones. In this study, the medication will be given to patients through an intravenous infusion, which means it is delivered directly into the bloodstream through a vein.

The purpose of the study is to determine if giving Zoledronic Acid early, within 5 days after hip fracture surgery, is as effective as giving it later, 3 months after surgery. The study will monitor the effects of the medication on bone health over a period of 12 months. Participants will be randomly assigned to receive either the early or late treatment, and some may receive a placebo. The study will also involve monitoring various health outcomes, such as the ability to move around, the occurrence of delirium, and any changes in bone density.

Throughout the study, participants will be closely observed to ensure their safety and to gather information on how the treatment affects their recovery from a hip fracture. The trial aims to provide valuable insights into the best timing for administering Zoledronic Acid to improve bone health and recovery in patients with hip fractures. The study is expected to continue until June 2026.

1 joining the trial

Upon joining the trial, eligibility is confirmed based on criteria such as age, hip fracture type, and kidney function.

Informed consent is required, either from the patient or a next of kin.

2 surgery and initial treatment

Surgery for the hip fracture is performed within 72 hours of the fracture.

Post-surgery, the patient is monitored for early mobilization and any signs of delirium.

3 administration of zoledronic acid

Zoledronic acid is administered through an intravenous infusion.

The timing of the infusion is randomized: either within 5 days after surgery or 3 months post-surgery.

4 monitoring and follow-up

The patient’s bone health is assessed by measuring bone turnover markers, such as P1NP, 12 months after treatment.

Secondary assessments include mobilization scores, incidence of fever, antibiotic use, and any new fractures or hospital readmissions.

5 completion of the trial

The trial is expected to conclude by June 2026.

Final evaluations will determine the effectiveness and safety of early versus late administration of zoledronic acid.

Who Can Join the Study?

The patient must have had one low energy hip fracture. This means the fracture happened from a minor fall or accident, not a major trauma.
The patient must have had surgery within 72 hours after the hip fracture.
The patient must be over 50 years old. If the patient is a woman aged 50-60, she must be postmenopausal (no longer having menstrual periods) or not pregnant.
The patient must have acceptable kidney function. This is measured by something called estimated GFR, which should be greater than 35. The patient should also have normal calcium levels in the blood.
The patient must be considered fit to complete the follow-up by the doctor in charge of recruiting for the study. This means the patient is healthy enough to participate in all parts of the study.
The patient or their next of kin must have signed informed consent. This means they agree to participate in the study after understanding what it involves.

Who Cannot Join the Study?

Patients who have had a hip fracture cannot participate.
Patients who are not within the specified age range cannot participate. The age range includes adults and older adults.
Both male and female patients are considered, but specific criteria may exclude some based on gender-related factors.
Patients who are part of a vulnerable population are not eligible. This means people who might need special protection or care.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country	Status
Oslo Universitetssykehus HF	Oslo	Norway

Other Sites

Site Name	City	Country	Status
Diakonhjemmet Sykehus AS	Oslo	Norway
Vestre Viken HF	Drammen	Norway

Trial status

Country	Status	Recruitment Start
Norway	Not recruiting	01.12.2021

Trial locations

Investigated drugs:

Zoledronic Acid

Zoledronate is a medication used in this trial to help patients who have had hip fractures. It is given to see if it can effectively reduce bone turnover, which is a process where old bone is replaced by new bone. The trial is testing whether giving zoledronate early, within 5 days after hip fracture surgery, is as effective as giving it later, 3 months after surgery. The goal is to see if early treatment can help maintain bone strength and prevent further fractures.

Hip Fracture – A hip fracture is a break in the upper part of the thigh bone (femur) near the hip joint. It often occurs in older adults, especially those with weakened bones due to osteoporosis. The fracture typically results from a fall or direct impact to the hip area. Symptoms include severe pain in the hip or groin, inability to put weight on the leg, and stiffness or bruising around the hip. The condition can lead to complications such as reduced mobility and increased risk of further fractures. Recovery often involves surgery followed by rehabilitation to restore movement and strength.

Trial ID:

2023-510198-32-00

NCT ID:

NCT20122234

Trial Phase:

Therapeutic confirmatory (Phase III)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on Zoledronic Acid for Patients with Hip Fractures: Evaluating Early Treatment Safety and Effectiveness

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?